I. MODIFIED AGREEMENTS |
|||
Biotech Co.* | Pharma Co. (Country) | Change from | Terms/Details (Date) |
| | |||
Accelrys Inc. | AstraZeneca plc | Renewed unified global licensing agreement for Accelrys' simulation software | AstraZeneca uses the software to characterize therapeutic targets and to identify and optimize lead compound (10/10) |
Biotica | Pfizer Inc. | Expanded agreement for macrolide anti-infectives | Biotica will manipulate microbial polyketide biosynthetic pathways to produce macrolide templates for further chemical derivatization by Pfizer; the expansion adds new structure-based targets to the existing program; Pfizer will undertake development and marketing of any resulting candidates (9/24) |
Cortex Pharmaceuticals | Les Laboratoires | Expanded research collaboration to include the identification and development of Ampakine compounds that may be used to treat anxiety disorders | Cortex will receive $4M of research funding in eight payments of $500,000 each, and will be eligible for milestone payments and royalties (10/9) |
Neurocrine | Taisho | Restructured agreement for developing a diabetes product, giving Neurocrine the ability to reacquire and assume all rights to the product outside Japan | The deal involves NBI-6024 for diabetes mellitus (10/14) |
II. TERMINATED AGREEMENTS | |||
Acusphere | Elan Corp. | Terminated joint venture to develop and commercialize certain pulmonary drug delivery product candidates | The termination was a result of Elan's restructuring efforts and desire to focus on its core businesses in neurology, pain and autoimmune diseases (10/1) |
Cell Genesys | Japan Tobacco | Terminated agreement for prostate cancer and lung cancer vaccines | Cell Genesys regained all worldwide rights to its GVAX portfolio (10/18) |
Cephalon Inc. | Elan Pharma | Terminated agreement for Actiq | Cephalon reacquired rights to Actiq in 12 countries for $50M in cash; the agreement was part of Elan's restructuring efforts (10/3) |
Elite Pharmaceuticals | Elan Corp. | Termination of a joint venture, Elite Research Ltd. | Elite now owns 100% of the joint venture, which has completed a Phase I study with once-a-day Oxycodone formulation, and is developing a product in the central nervous system area; Elite agreed to pay a royalty on certain revenues from the Oxycodone payment (10/4) |
FeRx Inc.* | Elan Corp. | Terminated agreement in which FeRx regained all rights to MTC-DOX | The joint venture was established in October 2000 (9/26) |
Nastech Pharmaceutical | Schwarz | Terminated agreement for the rights to the Nascobal gel product for vitamin B-12 deficiency | Nastech regained the U.S. rights and will pay Schwartz $8.75M, plus interest, over a four-year period; the deal includes a $1.5M up-front payment (10/1) |
| | |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange | |||
